Personalizing prostate cancer therapy: The way forward - Abstract

Advances in genomic sequencing and molecular characterization are improving our understanding of the biology of prostate cancer and challenging us to translate emerging data into meaningful clinical outcomes.

Several recently approved treatments for advanced prostate cancer extend survival; however, these therapies are not personalized based on predictive biomarkers. Innovative strategies for early phase drug testing that harness our growing knowledge of important prognostic markers and emerging predictive biomarkers are needed. In this review we discuss new strategies to assess drug response in early phase clinical trial testing.

Written by:
Cetnar JP, Beer TM.   Are you the author?
Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA.  

Reference: Drug Discov Today. 2014 Jul 18. pii: S1359-6446(14)00277-3.
doi: 10.1016/j.drudis.2014.07.006


PubMed Abstract
PMID: 25046532

UroToday.com Prostate Cancer Section

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe